Leerink analyst Michael Cherny lowered the firm’s price target on Doximity (DOCS) to $25 from $31 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity downgraded to Neutral from Buy at BTIG
- Doximity Maintained at Buy as Analyst Sees Temporary Profit Trough and Long-Term Upside with Unchanged $47 Price Target
- Doximity: Buy Rating Backed by Solid Q4 Results, Cyclical Pharma Headwinds, and Long-Term AI Growth Strategy
- Doximity downgraded to Equal Weight from Overweight at Wells Fargo
- Doximity downgraded to Neutral from Outperform at Baird